8-K: Nektar's Rezpegaldesleukin Shows Promise in Alopecia Areata

Nektar Therapeutics announced positive topline results from its Phase 2b REZOLVE-AA trial for alopecia areata, establishing proof-of-concept and supporting advancement to Phase 3.

Summary

• Nektar Therapeutics reported topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA (alopecia areata) clinical trial, involving 92 patients with severe-to-very-severe alopecia areata.
• Patients were randomized to receive one of two rezpegaldesleukin doses (24 g/kg or 18 g/kg) or placebo, administered subcutaneously twice-monthly.
• The primary endpoint, mean percentage reduction from baseline in the Severity of Alopecia Tool (SALT) score at Week 36, narrowly missed statistical significance in the initial analysis, with reductions of 28.2% for 24 g/kg (p=0.186), 30.3% for 18 g/kg (p=0.121), and 11.2% for placebo.
• When excluding four patients with major study eligibility violations, both rezpegaldesleukin treatment arms met statistical significance on the primary endpoint: 29.6% for 24 g/kg (p=0.049), 30.4% for 18 g/kg (p=0.042), and 5.7% for placebo.
• The absolute treatment effect for rezpegaldesleukin arms was similar with or without the exclusion of eligibility violations, with one placebo patient's exclusion accounting for a 5.5% difference in placebo performance.
• Both rezpegaldesleukin treatment arms showed a dose-dependent clinical treatment effect compared to placebo on key secondary endpoints of SALT ≥30, SALT ≥20, and SALT ≥10.
• A favorable safety and tolerability profile was observed, consistent with prior studies, with nearly all treatment-emergent adverse events (TEAEs) being mild-to-moderate in severity and self-resolving.
• The discontinuation rate due to adverse events was low at 1.4% in the combined rezpegaldesleukin treatment arms, with no patients discontinuing due to injection site reactions (ISRs).
• No increased risk of major adverse cardiovascular events, thrombosis, infection, acne, or oral herpes was observed for rezpegaldesleukin-exposed patients compared to placebo.

Sentiment

Score: 8

Explanation: The trial results, particularly after excluding ineligible patients, demonstrate clear efficacy and a favorable safety profile, establishing proof-of-concept and supporting advancement to Phase 3. This positions rezpegaldesleukin as a potentially superior alternative to existing treatments for alopecia areata.

Positives

• Achieved statistical significance on the primary endpoint (mean percent SALT reduction at Week 36) when excluding four patients with major study eligibility violations (p=0.049 for 24 g/kg, p=0.042 for 18 g/kg), meeting the target product profile.
• Both rezpegaldesleukin dose arms more than doubled the SALT score reduction treatment effect observed with placebo.
• A favorable safety and tolerability profile was observed, consistent with prior studies, with nearly all treatment-emergent adverse events (TEAEs) mild-to-moderate in severity and self-resolving.
• The discontinuation rate due to adverse events was low at 1.4% in the combined rezpegaldesleukin treatment arms.
• No increased risk of major adverse cardiovascular events, thrombosis, infection, acne, or oral herpes was observed, differentiating it from JAK inhibitors.
• Demonstrated proof-of-concept for rezpegaldesleukin in alopecia areata, supporting planned advancement to Phase 3 development.
• Established 24 g/kg as the optimal dose for Phase 3 in inflammatory skin diseases.
• Observed meaningful hair growth, including eyebrow and eyelash regrowth, in treated patients.
• Rezpegaldesleukin received Fast Track designation from the FDA for severe alopecia areata in July 2025.

Negatives

• The primary endpoint narrowly missed statistical significance in the initial modified intent-to-treat (mITT) analysis (p=0.186 for 24 g/kg, p=0.121 for 18 g/kg).
• Statistical significance for the primary endpoint was only achieved after excluding four patients with major study eligibility violations.
• The study was not powered to demonstrate statistical significance for secondary endpoints.

Risks

• The therapeutic potential of rezpegaldesleukin is based on preclinical and clinical findings and observations and is subject to change as research and development continue.
• Rezpegaldesleukin is an investigational agent, and its continued research and development is subject to substantial risks, including negative safety and efficacy findings in future clinical studies.
• Rezpegaldesleukin is in clinical development, and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval.
• A Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Patents may not issue from the company's patent applications, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required.
• Preliminary and interim data from clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.
• Dependence on third parties to conduct clinical trials.
• Risks regarding future capital requirements.
• Dependence on collaboration agreements.
• Reliance on contract manufacturers and suppliers.
• Risks related to legal proceedings and related litigation costs and liabilities.

Future Outlook

Nektar Therapeutics plans to advance rezpegaldesleukin into a Phase 3 program for the treatment of alopecia areata in 2026, leveraging its existing Fast Track designation. The company expects to make data from the 16-week treatment extension available in early Q2 2026 and intends to submit the REZOLVE-AA results for presentation at a medical conference in 2026.

Management Comments

• Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, stated: "As physicians, we have long been in search of an effective biologic for alopecia areata, given the safety limitations and prescribing burden of JAK inhibitors. Importantly, this is the first biologic to show a truly meaningful level of clinical effect in patients, which could expand the number of patients we can treat with this immune disorder."
• David Rosmarin, MD, Chair of the Department of Dermatology and Associate Professor of Dermatology at the Indiana University School of Medicine, added: "These study results demonstrate that treatment with rezpegaldesleukin can lead to meaningful hair regrowth in patients with alopecia areata, including eyebrow and eyelash growth. Importantly, this occurs without the burdens of intensive testing and monitoring for dermatologists and without serious safety concerns. Currently, the only biologic recommended in national guidelines for alopecia areata is dupilumab, which has demonstrated only marginal efficacy. These data suggest that rezpegaldesleukin is a safe and well-tolerated biologic that should be advanced into Phase 3 development as a first-line treatment for patients with severe-to-very-severe alopecia areata, and potentially for those with moderate disease."
• Howard W. Robin, President and CEO of Nektar Therapeutics, commented: "With outstanding results already achieved for rezpegaldesleukin in our atopic dermatitis study, these REZOLVE-AA data now provide clear proof of concept in a second, large potential indication, thereby broadening the number of patients that could benefit from this first-in-class Treg mechanism. In 2026, we plan to advance rezpegaldesleukin into a Phase 3 program for the treatment of alopecia areata and leverage rezpegaldesleukins existing Fast Track designation with the goal of making this important potential treatment available to patients worldwide as soon as possible."

Industry Context

Alopecia areata is a widespread autoimmune disease with a significant unmet medical need for effective and safe long-term treatments. Current therapeutic options, such as JAK inhibitors, are associated with significant safety concerns, including boxed warnings and the need for intensive monitoring, which limit their chronic use and prescribing burden for physicians. Dupilumab, the only biologic currently recommended in national guidelines, offers only marginal efficacy. Rezpegaldesleukin, as a potential first-in-class IL-2 pathway agonist and regulatory T-cell proliferator, presents a differentiated safety profile without the burdens of JAK inhibitors, positioning it as a promising and potentially first-line biologic treatment for severe-to-very-severe alopecia areata, addressing a critical gap in the market.

Comparison to Industry Standards

• Rezpegaldesleukin's safety profile is highly differentiated from the JAK inhibitor class, which carries boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis, and requires extensive testing and monitoring.
• The clinical efficacy data for rezpegaldesleukin in alopecia areata, with a mean percent SALT reduction of approximately 30% at Week 36 (excluding ineligible patients), is similar to low-dose Olumiant (a JAK inhibitor) but with a superior and differentiated safety profile.
• Dupilumab, the only biologic currently recommended in national guidelines for alopecia areata, has demonstrated only marginal efficacy, whereas rezpegaldesleukin has shown a "truly meaningful level of clinical effect" and is suggested for advancement into Phase 3 as a first-line treatment.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, potential for Phase 3 advancement, and a differentiated product in a large, underserved market, enhancing future revenue prospects.
• Patients with Alopecia Areata: Potential for a new, effective, and safer treatment option compared to existing therapies, offering meaningful hair regrowth without the burdens of intensive monitoring and serious safety concerns.
• Physicians/Dermatologists: Provides a biologic option that is easier to prescribe and manage due to a favorable safety profile and no need for extensive lab monitoring, addressing a significant unmet need in clinical practice.

Next Steps

• Submit REZOLVE-AA results for presentation at a medical conference in 2026.
• Advance rezpegaldesleukin into a Phase 3 program for the treatment of alopecia areata in 2026.
• Data from patients ongoing in the 16-week treatment extension will be available in early Q2 2026.

Key Dates

Recommendation

The positive Phase 2b results for rezpegaldesleukin in alopecia areata, demonstrating statistically significant efficacy with a highly differentiated and favorable safety profile compared to current standards like JAK inhibitors and dupilumab, represent a significant de-risking event for Nektar Therapeutics. The establishment of proof-of-concept in a second major inflammatory skin disease, coupled with Fast Track designation and plans for Phase 3 advancement, indicates strong commercial potential in a large, underserved market. This outcome significantly enhances the company's pipeline value and future revenue prospects, making it a compelling "strong buy" for long-term investors.

Keywords

Nektar Therapeutics, NKTR, rezpegaldesleukin, REZPEG, alopecia areata, AA, clinical trial, Phase 2b, REZOLVE-AA, SALT score, regulatory T-cells, Treg, IL-2 pathway agonist, biotechnology, dermatology, autoimmune disease, drug development, Fast Track designation